Related Experiment Video
Updated: Jan 1, 2026
09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.6K
BrightFocus Alzheimer's Fast Track 2019.
Keith W Whitaker1, Frank M LaFerla2, Harry W M Steinbusch3
1BrightFocus Foundation, 22512 Gateway Center Dr, Clarksburg, MD, 20871, USA.
Molecular Neurodegeneration
|December 22, 2019
Summary
This workshop offers early-career scientists insights into Alzheimer's disease research trends. Participants will learn to secure funding for Alzheimer's disease projects.
Area of Science:
- Neuroscience
- Biomedical Research
Background:
- Alzheimer's disease is a progressive neurodegenerative disorder.
- Early-career scientists require specialized training in emerging research areas.
- Securing research funding is critical for scientific advancement.
Purpose of the Study:
- To provide graduate students and postdoctoral fellows with an intensive overview of Alzheimer's disease research.
- To equip participants with skills in grant writing and defense for Alzheimer's disease projects.
- To foster expertise in the future directions of Alzheimer's disease research.
Main Methods:
- A 3-day intensive workshop format.
- Focus on current trends and future directions in Alzheimer's disease research.
- Training modules on grant application writing and defense strategies.
Main Results:
- Participants gain comprehensive knowledge of the Alzheimer's disease research landscape.
- Enhanced skills in developing and defending research funding proposals.
- Increased preparedness to contribute to Alzheimer's disease research.
Conclusions:
- The "Alzheimer's Fast Track" workshop effectively prepares early-career scientists for leadership in Alzheimer's disease research.
- The program addresses critical needs in scientific training and funding acquisition.
- Investing in such specialized training accelerates progress in combating Alzheimer's disease.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
709
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
709
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:30Dementia
463
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
463
01:24Parkinson's Disease: Treatment
890
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
890
01:15Parkinson's Disease: Overview
1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
01:26Aging
537
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
537